GALE Study (Protocol number: APL2-GA-305)
A 36 month, phase 3 open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy secondary to age-related macular degeneration.
ClinicalTrials.gov Identifier: NCT04770545
Principal Investigator: Dr Fred Chen
For further information about this study, you may visit the Clinical Trial Registry:
https://clinicaltrials.gov/ct2/show/NCT04770545?term=pegcetacoplan&cond=Macular+Degeneration%2C+Age+Related&cntry=AU&draw=2&rank=2
Or contact the Lions Eye Institute Clinical Trials Office telephone (08) 9381 0750 or email lionsvisiontrials@lei.org.au.
